Wall Street couple helped push for first potential treatment of spinal muscular atrophy. If the Food and Drug Administration approves the drug, called nusinersen, it could help many people and show how private industry, philanthropists and patients can join forces to promote research into specific diseases.
Story here by Doni Bloomfield/Bloomberg
Photographs by Uno Yi/Bloomberg
